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Abstract
Background: Depletion of blood glutathione (GSH), a key antioxidant, is known to occur in preterm infants.
Objective: Our aim was to determine: 1) whether GSH depletion is present at the time of birth; and 2) whether it is associated
with insufficient availability of cysteine (cys), the limiting GSH precursor, or a decreased capacity to synthesize GSH.
Methodology: Sixteen mothers delivering very low birth weight infants (VLBW), and 16 mothers delivering healthy, full term
neonates were enrolled. Immediately after birth, erythrocytes from umbilical vein, umbilical artery, and maternal blood were
obtained to assess GSH [GSH] and cysteine [cys] concentrations, and the GSH synthesis rate was determined from the
incorporation of labeled cysteine into GSH in isolated erythrocytes ex vivo, measured using gas chromatography mass
spectrometry.
Principal Findings: Compared with mothers delivering at full term, mothers delivering prematurely had markedly lower
erythrocyte [GSH] and [cys] and these were significantly depressed in VLBW infants, compared with term neonates. A strong
correlation was found between maternal and fetal GSH and cysteine levels. The capacity to synthesize GSH was as high in
VLBW as in term infants.
Conclusion: The current data demonstrate that: 1) GSH depletion is present at the time of birth in VLBW infants; 2) As VLBW
neonates possess a fully active capacity to synthesize glutathione, the depletion may arise from inadequate cysteine
availability, potentially due to maternal depletion. Further studies would be needed to determine whether maternal-fetal
cysteine transfer is decreased in preterm infants, and, if so, whether cysteine supplementation of mothers at risk of
delivering prematurely would strengthen antioxidant defense in preterm neonates.
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Introduction
Premature birth abruptly propels the fetus from the protected,
relatively hypoxic intrauterine milieu into an environment with a
high oxygen pressure, and further exposes the preterm infant to
free radical injury from mechanical ventilation strategies, includ-
ing the use of high inspired oxygen fractions or inhaled nitric
oxide, and from reactive oxidative species (ROS) produced by
sepsis and/or inflammatory response. Physiological perturbation is
further enhanced because preterm have diminished antioxidant
defenses and are highly vulnerable to oxidative stress [1]. Evidence
for peroxidation of lipids and proteins is found in several tissues in
premature infants [2,3], and oxidative stress is involved in the
pathophysiology of several diseases associated with prematurity,
such as retinopathy, bronchopulmonary dysplasia (BPD) and
necrotizing enterocolitis [4].
The tripeptide glutathione (GSH), or L-c-glutamyl-L-cystei-
nyl-glycine, is the most abundant intracellular antioxidant and is
actively produced in nearly all mammalian cells, where its
concentration reaches the millimolar range. The maintenance of
intracellular GSH stores depends on the capacity of the cell’s
enzymatic equipment for GSH synthesis, the availability of
precursor substrates, and the cell’s ability to recycle oxidized
glutathione (GSSG) into its active reduced form, GSH.
Depletion of blood GSH has been demonstrated in premature
infants after a few days of life [5,6], and blood GSH correlates
with gestational age [5]. Cysteine availability has been
considered limiting for the synthesis of GSH in other
pathological situations, such as malnutrition or human immu-
nodeficiency virus infection, since providing cysteine has been
shown to stimulate GSH synthesis and restore GSH stores in
such situations [7,8].
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transsulfuration pathway producing cysteine from methionine and
serine via homocysteine, is not fully active, since activity of
cystathionine-c-lyase is barely detectable in human fetal tissues [9–
15]. Although both enterally [16] and parenterally [17] fed
premature infants have been shown to be able to produce cysteine,
the capacity for intrahepatic de novo cysteine synthesis appears to be
directly proportional to the maturity of the neonate [10].
Nevertheless, providing cysteine even in high doses to preterm
infants after birth seems neither to increase [GSH] nor to enhance
GSH synthesis rate [18].
To obtain further insight into the mechanisms involved in the GSH
deficiency observed in premature infants, we have compared the
[GSH] and [cys] in umbilical cord blood from very low birth weight
infants (VLBW) (gestational age (GA),32 weeks and/or birth weight
,1500g) with those of healthy full term newborns. Fractional synthesis
rates of GSH, (FSRGSH) were also determined in vitro by following the
incorporation of L-[
2H2]cysteine into erythrocyte glutathione. All
measurements were performed in blood erythrocytes obtained
immediately after birth from umbilical arteries and veins and in
maternal venous blood. Erythrocytes were chosen for measurements
instead of plasma because of their highly active GSH synthesis
contributing in large amounts besides liver to the GSH pool of the
preterm. We hypothesized that the GSH depletion observed in
preterm infants would already be present at the time of birth, and may
be due to insufficient cysteine availability from maternofetal cysteine
transfer rather than to an insufficient capacity for GSH synthesis.
Methods
Design
The study was registered (ClinicalTrials.gov Identifier:
NCT00607061), and performed in the Department of Obstetrics
of the Ho ˆpital Me `re-et-Enfant at the University of Nantes after
approval by the local medical ethical committee (Comite ´d e
Protection des Personnes dans la recherche biome ´dicale (CPP) des
Pays de la Loire). The study was investigator-initiated and funded
by the Hospital of Nantes. Written, informed consent was
obtained from every mother, a few hours before delivery.
Umbilical cord blood samples were collected in the delivery
room simultaneously with sampling for blood gas analysis by the
midwife. As umbilical cord is routinely discarded after sampling,
the samples obtained for the current study did not involve any
additional blood loss for the neonates.
Umbilical cord blood was obtained from VLBW infants (n=16),
and inacontrolgroupofhealthy,full-termneonates(n=16)inorder
to determine [GSH]. Furthermore, FSRGSH were determined ex vivo
in erythrocytes obtained from half of the babies in the VLBW group
(n=8) and compared with half of the control groupofneonates born
at term (n=8). Assessment of FSRGSH in umbilical cord blood
erythrocytes necessitated immediate handling of samples after birth
with a narrow cooperation ofthe neonatal careteam and theGCMS
laboratory team. To obtain insight into the role of the materno-fetal
unit (including placenta) in cysteine and GSH exchange, all analyses
were performed in blood from three sites: the umbilical vein
providing information about blood directed from the placenta to the
fetus; in samples collected from one of the two umbilical arteries
representing bloodof thefetusredistributed to placenta;and inorder
to relate these results to the status of the mothers, we also collected
maternal venous blood samples at delivery.
Subjects
The subjects were 16 inborn VLBW infants born before 32
weeks of GA and/or with a birth weight ,1500 g, and a control
group of 16 inborn neonates born at term after an uneventful
pregnancy and delivery. Umbilical arterial and venous cord blood
was obtained immediately after birth. Maternal venous blood was
collected at delivery for every neonate included in order to obtain
maternal infant pairs for comparison between the preterm delivery
and the control group. In 8 VLBW infants chosen at random from
the 16 subjects, [GSH] and [cys] were determined and compared
with 8 healthy full term neonates also chosen at random. In the
remaining groups of 8 VLBW infants and 8 full-term infants, the
fractional synthesis rate of GSH, (FSRGSH), and [GSH] were
determined in order to compare them also to 8 full-term neonates
chosen at random.
Inclusion criterion for VLBW infants was a GA,32 weeks and/
or a birth weight ,1500 g. Inclusion criteria for the control group
were: a GA .37 weeks, and uneventful pregnancy and delivery.
Exclusion criteria for the VLBW group were: perinatal asphyxia
defined as pH,7.2 in umbilical cord blood and/or difference
between arterial and venous pH,0.2, or major fetal pathology
(abnormal karyotype, malformation, foetal pathology revealed
during pregnancy).
Exclusion criteria for control group were: perinatal asphyxia,
major fetal pathology, bacterial or viral infection, or maternal
arterial blood pressure .90 mm Hg during pregnancy.
Measurement of glutathione and cysteine concentrations
Using antioxidant dithiothreitol (DTT) that reduces all thiol
dimers, [GSH] was measured as total GSH (reduced GSH plus
oxidized GSH, the disulfide GSSG) and [cys] as total cysteine
(reduced cysteine plus oxidized cystine). Hence, values include
various GSH and cysteine-containing and protein-linked disul-
phides in addition to free monomers. Erythrocytes provided from
maternal, venous, and arterial umbilical cord blood were chosen
for measurements, as they are more readily available than tissue
samples and have a highly active GSH synthesis with an active
export towards plasma, contributing besides the liver to the
extracellular GSH pool. Umbilical cord blood is moreover easy to
collect and non invasive for the neonate. Determinations were
performed by gas chromatography-mass spectrometry using
homoglutathione as an internal standard, as previously described
[19].
Measurement of in vitro fractional rates of glutathione
synthesis (FSRGSH)
Previous work established optimal conditions to synthesize GSH
in vitro and thereby to determine FSRGSH [19-21].
Immediately after sampling in delivery room, freshly sampled
blood erythrocytes were washed twice by centrifugation of the
blood samples and replacement of the supernatant volume-by-
volume by 0.9% NaCl in order to remove enzymes contained on
the surface and potentially influencing glutathione metabolism.
Erythrocytes contained in the remnant phase after the last
centrifugation were disrupted by adding a volume of ice cold
distilled water equal to the volume of plasma discarded. A 2-mL
aliquot of lysed erythrocytes was then incubated at 37uC with
2 mL of a solution (adjusted to pH 7.5 with NaOH (10 mol/L))
containing: L-[
2H2]cysteine (98% enriched, Cambridge Isotopes,
Andover, Mass) at a concentration of 500 mmol/L, glutamate
(600 mmol/L), glycine (400 mmol/L), ATP (400 mmol/L), di-
thiothreitol (400 mmol/L), glucose (400 mmoL/L), MgCl2 (3
moL/L), and TrizmaH hydrochloride (400 mmol/L). Incubation
of red blood cell lysates with these adequate amounts of substrates
allowed determination of maximal FSRGSH. 400-ml aliquots were
removed at 0, 10, 20, 30, 60 and 90 min after the start of
incubation. The reaction was stopped immediately by the addition
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L sodium phosphate buffer (pH 7.5). After centrifugation (30006g
for 15 min at 4uC), the supernatant was removed, filtered and
each sample derivatized and analyzed by GCMS.
Calculations
Glutathione fractional synthesis rate (FSRGSH, %/d) was
determined from the incorporation of
2H2-cysteine into red blood
cell glutathione: FSRGSH=1006246(DEGSH/Dt)/Erbccys, where
Erbccys is the
2H2 enrichment in erythrocyte-free cysteine at
plateau, DEGSH/Dt is the slope (MPE/h) of the regression line
describing the rise in red blood cell
2H2-glutathione enrichment
(MPE) as a function of time (h) over the last 3 hours of incubation,
and 24 and 100 convert FSR to percent per day. FSRGSH
represents the fraction of glutathione pool synthesized per unit of
time.
Absolute synthesis rate (ASRGSH, mmol/L per day) was
calculated as:
ASRGSH = FSRGSH/100 6[GSH]
In earlier reports [19–21] and preliminary experiments (data
not shown) we confirmed the determination of FSR to be
reproducible, when it was measured in replicate samples from
healthy adult volunteers, with a coefficient of variation of ,5%
between replicate measurements.
Statistics
Statistical analysis was performed using SPSSH version 14.0
(SPSS, Chicago, IL). Results are reported as median and
interquartiles, and percentages were presented as percent [95%
confidence interval]. Mann-Whitney U and Chi
2 tests were used to
compare quantitative and proportion values, respectively. Spear-
man’s correlation test and regression analyses were used to
evaluate the relationship between maternal and venous umbilical
cord blood [cys] or [GSH]. Statistically significant differences were
defined as when p,0.05.
Results
A total of 16 VLBW infants and 16 full term neonates were
enrolled (Table 1). Half of the subjects (n=8) in each group were
randomly chosen and included for determination of [GSH] and
[cys] in arterial and venous umbilical cord blood. In the second
half of each group (n=8) both FSRGSH and [GSH] were
determined. Both subgroups of VLBW infants were similar
regarding gestational age and birthweight. All analyses were
performed simultaneously in the infants’ mothers.
Maternal and fetal erythrocyte GSH concentrations
Maternal blood [GSH] was significantly lower in mothers giving
b i r t hb e f o r et e r mt h a ni nt h o s ew h od e l i v e r e da tf u l lt e r m( m e d i a n :
337 mmol/L, [interquartile, 310–479 mmol/L] vs. median: 656 mmol/
L, [interquartile, 494–858 mmol/L]; p=0.0003) (Figure 1A). Neither
growth retardation nor preeclampsia (data not shown) was associated
with lower maternal GSH levels than prematurity itself.
Similarly, [GSH] in umbilical venous cord blood was significantly
lower inVLBW compared with fullterm infants (median: 509 mmol/
L, [interquartile, 461–625 mmol/L] vs. median: 868 mmol/L, [inter-
quartile, 711–1013 mmol/L]; p=0.001) (Figure 1B). This was also
the case for umbilical arterial blood [GSH] (434 mmol/L, [inter-
quartile, 363–540 mmol/L] vs. 668 mmol/L, [interquartile, 450–
733 mmol/L]; VLBW vs. full term; p=0.02), (Figure 1C). Arterial
umbilical cord blood [GSH] were lower than venous umbilical cord
blood [GSH] and this arterio-venous gradient was larger in full-term
than in premature infants (p=0.02).
Table 1. Selected clinical characteristics of enrolled infants and their mothers.
Preterm infants Full-term infants
(n=16) (n=16) p
Sex
Male, n 8 (50%) 7 (40%)
Female, n 8 (50%) 9 (60%)
Birth weight, g 1160 [982–1317] 3490 [3305–3669] ,0.001
Gestational age, wk 29 [27–30] 40 [39–41] ,0.001
Birth weight, z score -0.4 [21.1–0.2] -0.1 [20.5–0.2] 0.29
Umbilical cord blood pH 7.3 [7.2–7.3] 7.3 [7.2–7.4] 0.14
Mode of delivery ,0.001*{
Vaginal, n 6 (40%) 16 (100%)
Cesarean section, n 10 (60%) 0 (0%)
Antenatal steroids 15 (94%) 0 (0%) ,0.001
Preeclampsia, n 6 (40%) 0 (0%) 0.02*{
Chorioamniotitis, n 8 (50%) 0 (0%)
Premature rupture of membranes (.12 hours antepartum), n 6 (40%) 0 (0%)
Apgar score at 5 min 10 [8–10] 10 [10–10] 0.12
Infant haemoglobin g/dL 14.5 [13.6–16.3] 16.3 [15.0–17.0] 0.05
Maternal age, y 27 [24–34] 30 [27–35] 0.34
Maternal haemoglobin g/dL 11.6 [11.0–12.2] 11.6 [11.0–12.2] 0.17
Data are reported as n (%) or median [interquartile]. { intra-group comparison of vaginal and cesarian delivery modes. { intra-group comparison of preeclampsia (Mann-
Whitney U or Chi
2 tests).
doi:10.1371/journal.pone.0027626.t001
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venous umbilical cord blood [GSH] (r
2=0.65; p=0.001)
(Figure 2A).
Maternal and fetal erythrocyte cysteine concentrations
Maternal blood [cys] was significantly lower in mothers who
delivered preterm, compared with full term (median: 31.3 mmol/
L, [interquartile, 26.8–33.2 mmol/L] vs. median: 62.0 mmol/L,
[interquartile, 53.2–99.7 mmol/L]; p=0.001), (Figure 3A). Sim-
ilarly, venous umbilical [cys] was significantly decreased in
VLBW compared with full-term neonates (median: 24.4 mmol/L,
[interquartile, 23.4–27.8 mmol/L] vs. median: 53.5 mmol/L,
[interquartile, 41.7–91.6 mmol/L]; p=0.001), (Figure 3B). Ac-
cordingly, a strong correlation was observed between maternal
and venous umbilical cord blood [cys] (r
2=0.62; P=0.001),
(Figure 2B).
Cysteine depletion was also found in umbilical arterial blood in
VLBW infants (median: 28.6 mmol/L, [interquartile, 23.7–
Figure 1. Glutathione concentration [GSH] in erythrocytes from maternal blood (A), venous umbilical cord blood (B) and arterial
umbilical cord blood (C) of preterm and full-term subjects. The boxplot shows the median (central horizontal line) and includes the
25
th (lower box border) to 75
th percentile (upper box border) of [GSH] (mmol/L). Preterm (n=16) were compared with full-term (n=16) subjects.
Significant differences were observed between the two groups (p,0.05), as assessed with the Mann-Whitney U test.
doi:10.1371/journal.pone.0027626.g001
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91.6 mmol/L]; p=0.006), (Figure 3C).
Glutathione fractional synthesis rates
As shown in Table 2, the fractional synthesis rates of GSH
(FSRGSH) determined in vitro in erythrocytes from VLBW infants
did not differ from those measured in full term infants, regardless
of the sampling site. When determined in arterial umbilical cord
blood, there was even a (non significant) trend toward higher
FSRGSH in VLBW infants than in full term infants. Absolute
synthesis rates (ASRGSH) did not differ. Similarly, the term of
delivery did not affect FSRGSH in maternal blood (Table 2).
Discussion
The findings of the current study demonstrate that blood
glutathione depletion is already present at the time of birth in
premature infants, compared with term infants. They further
suggest that GSH depletion is not due to a defect in fetal GSH
synthesis, as GSH synthetic rates measured in isolated erythrocytes
were indistinguishable in preterm and term infants. Critically,
evidence for a dramatic reduction in cysteine delivery to the
preterm fetus is provided, with a 40% reduction in umbilical cord
vein [cys] in preterm infants compared with term infants, and a
43% reduction in maternal blood from mothers delivering preterm
babies. Taken collectively, the data suggest that the depletion in
GSH associated with preterm birth may result from the
combination of 1) increased fetal GSH utilization and 2)
insufficient maternofetal cysteine delivery.
The first interesting finding in the current study was a significant
reduction in maternal [GSH] in the case of preterm delivery. The
effect of pregnancy on GSH status is debated, and published data
concerning maternal thiol concentrations are scarce. Even though
pregnancy generates increased oxidative burden, in normal
pregnancy antioxidant capacity increases with term [22]. The
plasma concentrations of cysteine, GSH and homocysteine are
lower in healthy, pregnant women at delivery than in nonpregnant
women, and plasma cysteine are lower in the 3
rd than 2
nd trimester
during uncomplicated pregnancy [23]. In preeclampsia, maternal
cysteine and homocysteine levels were comparable to those in
nonpregnant women, but GSH levels were lower, suggesting either
accelerated GSH utilization or insufficient GSH synthesis [24,25].
In our population, preterm delivery occurred in a context of
chorioamniotitis, premature rupture of membranes, or preeclamp-
sia. All are associated with inflammation, which is known to affect
redox balance [26]. In case of infection, bacterial products
stimulate the release of inflammatory cytokines by decidua and
fetal membranes, leading to preterm labor and generation of free
radicals and ROS in fetal and maternal circulation [27].
Accordingly, premature rupture of membranes involves damage
of collagen in the chorioamnion by tissue-damaging ROS
molecules [27]. Finally, elevated levels of oxidized thiols have
been reported in pregnancy complicated by preeclampsia [28]. A
lower antioxidant capacity has been implicated in syncytiotropho-
blast apoptosis and increased shedding into the maternal
circulation with endothelial dysfunction that is considered a
causative factor in the maternal hyperimmune response charac-
terizing preeclampsia [29,30]. In the current study, preeclampsia
was not associated with a further decline in maternal [GSH],
compared with other causes of preterm birth, suggesting depletion
of GSH is present regardless of the cause of preterm delivery and
due to increased oxidative stress. The majority of mothers
delivering preterm underwent a Caesarean section, versus none
among the mothers delivering at full term (Table 1). Although
preoperative fasting or stress due to the surgical procedure might
impact oxidative stress, we could not find an influence of C-section
on GSH (or cysteine) levels in this subgroup. Among the mothers
who delivered preterm, all but one received antenatal steroids
(Table 1), and antenatal steroids were found to attenuate oxidative
stress (assessed by GSH/GSSG ratio) and oxidative damage to
proteins and DNA [31]. The GCMS assay employed in our study
implies the reduction of GSSG to GSH and therefore cannot
distinguish between the reduced and the oxidized forms of GSH
and measures only total GSH. For this reason, we cannot evaluate
the capacity of the mother to regenerate GSH from GSSG. Yet
the lower total glutathione, combined with unaltered GSH FSR
(Table 2), suggests increased rates of GSH utilization in our
population of mothers delivering preterm. Finally, as we only
measured glutathione FSR in erythrocytes, we cannot draw any
conclusion on the synthetic rate of GSH in maternal liver. Liver
indeed is the main source of plasma GSH, and hepatic GSH
synthesis might be assessed through a determination of GSH
synthetic rate in plasma; the assay we used is, however, not
sensitive enough to measure GSH synthesis in plasma, which has a
Figure 2. Correlation between glutathione concentration [GSH]
(A) or cysteine concentration [cys] (B) in venous umbilical cord
of preterm and full-term subjects and their maternal blood.
[GSH] or [cys] in venous umbilical cord blood are positively and
significantly correlated with those in maternal blood (R
2=0.65; p,0.05
for GSH and R
2=0.62; p,0.05 for cysteine) as assessed with the Mann-
Whitney U test.
doi:10.1371/journal.pone.0027626.g002
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in erythrocytes). Erythrocyte GSH nevertheless accounts for the
bulk of whole blood GSH, and may play a role in antioxidant
defence even in extracellular medium [32].
In the VLBW infant group, we observed a significantly lower
[GSH] determined in venous umbilical cord blood, which likely
represents the sum of the GSH distributed from the placenta into
fetal circulation and GSH produced by fetal erythrocytes. Even
though earlier studies by Frosali et al [33] and Jean-Baptiste et al
[34], found similar umbilical cord blood [GSH] between preterm
and term infants, the population enrolled in the current study
may not be strictly comparable, as the average birth weight was
1160g in our study, compared with 1734 and 1827 g in the
studies by Frosali et al and Jean-Baptiste et al, respectively. We
speculate that the slightly lower gestational age of the preterm
infants enrolled in the current study may account for the
difference with these earlier studies [33,34]. In studies performed
several days after birth GSH depletion was observed in preterm
infants before, with the lowest GSH content observed in the less
mature infants: lower [GSH] in premature than in term
newborns has been found in peripheral venous blood following
birth with a more pronounced decrease of lymphocyte [GSH] on
day 2 from birth on [5], and in erythrocytes of preterm with
respiratory distress syndrome [6]. In cells from tracheal aspirates
derived from oxygen-dependant newborn infants, intracellular
total [GSH] has been found lower in male and in less mature
infants [35]. Another study confirmed that GSH content in
tracheal aspirates from preterm with IRDS is decreased [36].
Our study is first to demonstrate that GSH depletion is present in
preterm infants as early as at the time of birth as we measured
[GSH] in umbilical cord blood in the delivery room. We
speculate that in the very preterm infants enrolled in the current
study, either (a) GSH was depleted prior to birth due to the
underlying cause of prematurity, or (b) the process of birth per se
contributed to a precipitous drop in GSH during birth, resulting
in low cord blood GSH at the time of sampling.
Figure 3. Cysteine concentration [cys] in erythrocytes from maternal blood (A), venous umbilical cord blood (B) and arterial
umbilical cord blood (C) of preterm and full-term subjects. The boxplot shows the median (central horizontal line) and includes the
25
th (lower box border) to 75
th percentile (upper box border) of cysteine concentration (mmol/L). Preterm (n=8) were compared with full-term (n=8)
subjects. Significant differences were observed between the groups (p,0.05) as assessed with the Mann-Whitney U test.
doi:10.1371/journal.pone.0027626.g003
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of transition from fetal to neonatal life when the newborn is
exposed to an oxidative environment, and GSH depletion may
affect outcome, since oxidative-stress participates in the patho-
physiology of necrotizing enterocolitis, retinopathy, periventricular
leukomalacia and chronic lung disease [5,33,34]. Low plasma
GSH levels during the first hours of life have indeed been found in
infants with respiratory distress syndrome (RDS) [37] and in
infants who later developed BPD [38].
As for cysteine, we observed cysteine depletion in VLBW infants
and their mothers. The low cysteine levels observed in mothers of
preterm infants are intriguing. From a theoretical standpoint,
several factors could contribute to low maternal cysteine
concentration, including: (a) insufficient dietary methionine intake;
(b) poor conversion of methionine to cysteine; or (c) excess
utilization of cysteine via cysteine utilization for glutathione
synthesis or incorporation into body protein. The mothers of
preterm infants had been hospitalized for an average of 10.2 days
(versus 0.2 days for the group delivering at term) prior to delivery.
So they ingested hospital food rather than home cooked food. The
diet plan offered to the mothers was a regular hospital diet
providing 2600 kcal/d with 16% protein, and an estimated
methionine + cysteine content of 4200 mg/d, which exceeds the
estimated requirements for adults (<13 mg/kg/d, i.e., 780 mg/d
for an adult of average body weght) [39]. However, dietary intake
was not monitored through their hospital stay, and the mothers
may not have consumed their entire meals, since insufficient intake
has long been documented among patients during hospital stay:
for instance, in a recent European multicenter study, more than
half of the patients did not eat their full meal provided by the
hospital [40]. Whether the conversion of methionine to cysteine
operated normally cannot be ascertained, as we did not measure
methionine concentration; impaired conversion is, however,
unlikely as the conversion occurs in liver and liver function was
not altered in delivering mothers Increased utilization of cysteine
for glutathione synthesis is, however, likely as most mothers who
delivered prematurely did so because of conditions known to be
associated with inflammation, and inflammation invariably is
associated with increased oxidative stress, which, in turn enhances
glutathione synthesis. Maternal cysteine depletion therefore likely
results from the underlying disease that led to preterm delivery.
Cysteine levels must be sufficiently high to meet the require-
ments both for protein synthesis and the production of GSH, but,
conversely, must be kept below the threshold of cytotoxicity. GSH
synthesis decreases with sulfur amino acid intakes that are
marginal but adequate for protein synthesis, suggesting protein
synthesis has a higher priority for cysteine than does GSH
synthesis [41,42].
Our results suggest that umbilical venous cord blood [cys] may
directly depend on maternal levels. Energy-dependent transfer of
amino acids is the preferred route for essential amino acids, with
little or no metabolism within the placenta [43], whereas non-
essential amino acids may be processed, interconverted or
consumed within the placenta. Cysteine entry to the fetal
circulation is mediated by system xc
-, a transport protein which
transports cysteine in exchange for glutamate. Therefore, as
cysteine is the rate-limiting precursor for GSH synthesis, the
intracellular level of GSH is regulated by system xc
- activity
[43–45].
Cysteine may be a conditionally essential amino acid for
preterm infants since cystathionase, a key enzyme catalyzing the
last step of the transsulfuration pathway, cleaving cysteine from
cystathionine, is undetectable in fetal liver, with activity appearing
only postnatally [9]. In premature neonates, the low activity is
associated with higher cystathionine and lower [cys] in plasma
[15]. Both plasma cysteine [15] and hepatic de novo cysteine
synthesis [10] rise in proportion to gestational age. Even though
low plasma [cys] have been found in preterm infants receiving
cysteine-containing parenteral amino acid solutions [46,47]
cysteine deficiency seems to be relative, since both enterally-[16]
and parenterally-fed [10,17] premature infants are able to produce
cysteine. Demand may, however, exceed synthesis in case of RDS,
as lower erythrocyte [cys] were observed in preterm infants on day
0, and in those who developped BPD or who died, both
erythrocyte [cys] and [GSH] were found impaired on day 1 [39].
In the current study both GSH and cysteine were depleted in
preterm infants at the time of birth, compared with term infants.
The two substrates indeed are tightly linked. First, depletion of
GSH decreases the synthesis of S-adenosylmethionine (SAM) by
inhibition of L-methionine-S-adenosyltransferase [48,49]. As SAM
is an allosteric activator of cystathionine b synthase, transsulfura-
tion is impaired and homocysteine is preferentially diverted to the
transmethylation pathway [50], resulting in a lower cysteine
availability for GSH synthesis. Accordingly, in a model of preterm
baboon, supplementation with GSH, but not cysteine, prevented
the decline in cysteine occurring postnatally [51]. Secondly, GSH
is considered a cysteine reservoir, and low cysteine availability may
increase GSH breakdown.
Besides cysteine, glutamate and glycine, the other two
precursors of GSH, may affect fetal GSH availability. Glycine
indeed is considered a conditionally essential amino acid in the
neonate [52], and arises from the placental conversion of serine by
serine hydroxymethyltransferase, which has a low activity in
human placenta [53,54], whereas glutamate, is known to arise
from the conversion of glutamine in fetal liver [55]. As the assay
used in this study was developed to specifically assess GSH and
cysteine, we cannot ascertain whether glutamate and/or glycine
deficiency contributed to GSH depletion in VLBW cord blood.
The FSR measured ex vivo in the current study are approxi-
mately 5 times higher than those measured in vivo, e.g., 234% per
day in umbilical arterial blood in preterm infants in this study,
compared with approximately 45% per day in studies by Te
Braake et al [56]. Several factors obviously contribute to the
Table 2. Glutathione FSR (FSRGSH) and ASR (ASRGSH)i n
umbilical cord venous and arterial blood erythrocytes of
preterm and full-term infants and in erythrocytes from their
respective mothers.
Group
Preterm
birth
Full-term
birth
(n=8) (n=8) p
FSR, %/d
Umbilical vein 145 [79–174] 98 [75–126] 0.11
Umbilical artery 234 [84–256] 93 [72–115] 0.08
Maternal vein 110 [81-238] 77 [65-115] 0.16
ASR, mmol/L per day
Vein 740 [515–906] 663 [560–969] 0.79
Artery 651 [391–1222] 551 [442–634] 0.46
Data are reported as median [interquartile]. No differences were observed
between the samples collected at different gestational ages (p.0.05) as
assessed with the Mann-Whitney U test.
doi:10.1371/journal.pone.0027626.t002
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collected erythrocytes are lyzed, so equilibration of substrates
between extra- and intracellular milieus become immaterial; and
(b) erythrocytes are incubated with very high concentrations of all
glutamate, cysteine and glycine, that largely exceed concentrations
occurring in vivo. The in vitro method therefore measures the
maximal capacity for GSH synthesis, when the erythrocyte
enzymatic machinery is experiencing unlimited supply of precur-
sor amino acids.
In the current study, the FSRGSH, measured ex vivo in neonatal
erythrocytes, was indistinguishable between preterm and term
infants, and close to maternal values (Table 2). This suggests that
the observed GSH depletion may be due to increased utilization
and/or insufficient substrate availability rather than to immaturity
of synthetic capacity. This is in agreement with the early
maturation of the enzymatic activity for GSH synthesis docu-
mented in earlier studies [9,57]. GSH is synthesized from
glutamate, cysteine, and glycine in two consecutive steps by the
action of c-glutamylcysteine synthetase (GCS), which is rate-
limiting, and GSH synthetase. GCS activity levels have been
found in the same range in human foetal erythrocytes [58],
leukocytes [57], liver [59], lung and kidney as are found in adults
[60]. Short term regulation of GSH production by GCS occurs
mainly via the availability of cysteine. The Km of rat liver GCS for
cysteine is 100 mmol/L, near the upper end of typical cellular
[cys], and the rate of GSH synthesis is extremely sensitive to
changes in cellular cysteine level. GSH synthesis increases when
intracellular cysteine levels increase as a result of increased
saturation of GCS with cysteine, and this contributes to removal of
excess cysteine. When cysteine levels drop, GCS activity increases
and the increased capacity for GSH synthesis facilitates conser-
vation of cysteine in the form of GSH, although the absolute rate
of GSH synthesis still decreases because of the lack of substrate.
Our results showing fully efficient FSRGSH in prematures are in
agreement with this mechanism.
The unaltered FSRGSH observed for the VLBW infants in the
current study concurs with a recent study that found no difference
in FSRGSH on day 2 in prematures (,1500 g) receiving or not
from birth an amino acid supplement in their parenteral nutrition
[56]. Early amino acid infusion indeed increased blood [GSH] in
VLBW infants, without any change in GSH FSR, suggesting
amino acids may decrease GSH utilization, rather than increase
GSH synthesis [56,61]. Taken together, the findings from the
latter study and those from the current study point in the same
direction: that substrate availability may be the limiting factor of
maintaining adequate [GSH] after birth. Further studies using
maternal infusion of labeled cysteine may thus be warranted to
quantitate the rates of maternal-fetal cysteine transfer, and
establish whether such transfer is lower in VLBW than term
infants. If so, the supply of additional cysteine would become seem
a reasonable option. However, intervention studies with cysteine
supplied postnatally, even in high doses, failed to demonstrate an
impact on FSRGSH, nitrogen balance, or weight gain. This may
be, to some extent at least, because the included infants were not
critically ill, or because [GSH] was already adequate [18,62]. As
we show that deficiency is already present at the time of birth, and
as [cys] drops dramatically after birth in premature infants due to
either decreased cysteine synthesis, increased utilization, or
excretion, the inefficacy of post-natal cysteine delivery may be
due to a ‘late’ timing and it would be worthwhile to explore the
putative benefit of cysteine supply prenatally, as we find [cys] to be
consistently depleted in mothers of preterm infants.
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